SITC Archive Library

The Society for Immunotherapy of Cancer (SITC) hosted "Concurrent Session I: Presidential Session" during the SITC 31st Annual Meeting & Associated Programs on November 11-13, 2016. Available here are the presentation slides and video from the session.

Session Chair

• Howard L. Kaufman, MD, FACS – Rutgers Cancer Center Institute of New Jersey

Program Summary

The Presidential Travel Award recipients' abstracts were the top scoring among those submitted for the the SITC 31st Annual Meeting by young investigators, based on quality of research, excellence in results and methods, and the potential of their work to advance the field. Of the four Presidential Travel Award recipients, Roberta Zappasodi, PhD, Memorial Sloan Kettering Cancer Center, was selected to receive the Presidential Award based on his presentation during the Presidential Session on Saturday, November 12, 2016 in National Harbor, MD. Established in 1991, the SITC Presidential Award is the most prestigious Young Investigator Award and recognizes the young investigator deemed to have the most outstanding oral abstract presentation among those delivered in the Presidential Session of the SITC Annual Meeting.

About the SITC 31st Annual Meeting

SITC's 31st Annual Meeting provided a multidisciplinary educational and interactive environment focused on improving outcomes for current and future patients with cancer by incorporating strategies based on basic and applied cancer immunotherapy. The meeting consisted of cutting-edge research presentations by experts in the field, both oral and poster abstract presentations, and ample opportunity for structured and informal discussions, including important networking opportunities. In addition, the meeting included updates on major national and international initiatives coming from academia, government and industry, as well as important Society projects. Following SITC’s tradition of collaborating to advance the field, the 31st Annual Meeting featured numerous sessions collaboratively-developed with reputable organizations whose missions complement and align with that of SITC’s. An in-depth Value of Cancer Immunotherapy Summit, organized in collaboration with the American Society of Clinical Oncology, was prominently featured to discuss a crucial topic that impacts all cancer immunotherapy constituents, from researchers and clinicians to payers and cancer patients.

Intended Audience

The intended audience for this program includes U.S. and international researchers, regulators and healthcare professionals involved in cancer research and clinical care. This included, but was not limited to basic, translational and clinical researchers; postdoctoral fellows; oncologists; registered nurses; nurse practitioners; pharmacists; payers; and other allied health professionals.

Disclaimer: Due to the rapidly-evolving field of cancer immunotherapy, some of the content on this page may be out of date. For current information from SITC on cancer immunotherapy, scroll down to view Related Entries and Links.

#AnnualMeeting#Oncologist#2016#Clinician#SITC#Researcher#Biomarkers
#ClinicalTrials#Melanoma#PresentationSlides#Video#AdoptiveCellTherapy
#Nivolumab#Industry